Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Takeda Pharmaceutical Company Limited

We are investigating Takeda Pharmaceutical Company Limited (TAK) (“Takeda” or the “Company”) for potential violations of the federal securities laws. 

On May 14, 2019, Takeda forecast an unexpected operating loss for the current year, citing costs associated with the Company’s $59 billion purchase of Shire Plc.  On this news, Takeda’s American depositary receipt price fell $1.57 per share, or 8.06%, to close at $17.92 on May 14, 2019.